1 – 10 of 18
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
(
- Contribution to journal › Article
-
Mark
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy
(
- Contribution to journal › Article
-
Mark
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study
(
- Contribution to journal › Article
-
Mark
Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
(
- Contribution to journal › Article
-
Mark
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients : Design of the randomized controlled EVOLVD trial
(
- Contribution to journal › Article
- 2018
-
Mark
Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients
(
- Contribution to journal › Article
- 2017
-
Mark
Effect of Calcineurin Inhibitor-Free Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate after Heart Transplantation
(
- Contribution to journal › Article
-
Mark
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up : Results of a randomized controlled trial (SCHEDULE)
(
- Contribution to journal › Article